S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:CSTL

Castle Biosciences (CSTL) Stock Price, News & Analysis

$21.28
-0.31 (-1.44%)
(As of 03/27/2024 ET)
Today's Range
$21.09
$21.94
50-Day Range
$18.06
$25.30
52-Week Range
$9.26
$26.70
Volume
155,320 shs
Average Volume
257,232 shs
Market Capitalization
$584.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.00

Castle Biosciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
45.7% Upside
$31.00 Price Target
Short Interest
Bearish
5.17% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.77mentions of Castle Biosciences in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$1.17 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.01) to ($1.78) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.21 out of 5 stars

Medical Sector

555th out of 939 stocks

Medical Laboratories Industry

12th out of 19 stocks

CSTL stock logo

About Castle Biosciences Stock (NASDAQ:CSTL)

Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

CSTL Stock Price History

CSTL Stock News Headlines

Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
CSTL Apr 2024 17.500 call
Castle Biosciences Inc CSTL
Q4 2023 Castle Biosciences Inc Earnings Call
Castle Biosciences Inc (CSTL)
See More Headlines
Receive CSTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Castle Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/27/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:CSTL
Fax
N/A
Employees
610
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$31.00
High Stock Price Target
$37.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+45.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-57,470,000.00
Pretax Margin
-26.10%

Debt

Sales & Book Value

Annual Sales
$219.79 million
Book Value
$14.54 per share

Miscellaneous

Free Float
25,336,000
Market Cap
$584.14 million
Optionable
Optionable
Beta
0.90
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

CSTL Stock Analysis - Frequently Asked Questions

Should I buy or sell Castle Biosciences stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Castle Biosciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CSTL shares.
View CSTL analyst ratings
or view top-rated stocks.

What is Castle Biosciences' stock price target for 2024?

3 analysts have issued 12 month price targets for Castle Biosciences' shares. Their CSTL share price targets range from $25.00 to $37.00. On average, they anticipate the company's share price to reach $31.00 in the next year. This suggests a possible upside of 45.7% from the stock's current price.
View analysts price targets for CSTL
or view top-rated stocks among Wall Street analysts.

How have CSTL shares performed in 2024?

Castle Biosciences' stock was trading at $21.58 at the beginning of 2024. Since then, CSTL shares have decreased by 1.4% and is now trading at $21.28.
View the best growth stocks for 2024 here
.

Are investors shorting Castle Biosciences?

Castle Biosciences saw a increase in short interest in March. As of March 15th, there was short interest totaling 1,420,000 shares, an increase of 17.4% from the February 29th total of 1,210,000 shares. Based on an average daily volume of 252,100 shares, the short-interest ratio is presently 5.6 days.
View Castle Biosciences' Short Interest
.

When is Castle Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our CSTL earnings forecast
.

How were Castle Biosciences' earnings last quarter?

Castle Biosciences, Inc. (NASDAQ:CSTL) posted its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.74. The firm earned $66.12 million during the quarter, compared to the consensus estimate of $51.32 million. Castle Biosciences had a negative trailing twelve-month return on equity of 14.92% and a negative net margin of 26.15%.

What ETF holds Castle Biosciences' stock?

First Trust Nasdaq Lux Digital Health Solutions ETF holds 98 shares of CSTL stock, representing 0.21% of its portfolio.

What guidance has Castle Biosciences issued on next quarter's earnings?

Castle Biosciences updated its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $235.0 million-$240.0 million, compared to the consensus revenue estimate of $214.7 million.

What other stocks do shareholders of Castle Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Castle Biosciences investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), DexCom (DXCM), QUALCOMM (QCOM), Teladoc Health (TDOC), Applied Materials (AMAT), Incyte (INCY) and Intel (INTC).

When did Castle Biosciences IPO?

Castle Biosciences (CSTL) raised $50 million in an IPO on Thursday, July 25th 2019. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. SVB Leerink and Baird acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

Who are Castle Biosciences' major shareholders?

Castle Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Wasatch Advisors LP (9.63%), Granahan Investment Management LLC (8.05%), Principal Financial Group Inc. (5.89%), Vanguard Group Inc. (5.43%), Vanguard Group Inc. (5.32%) and Bellevue Group AG (4.58%). Insiders that own company stock include Adam Jay Sussman, Bernhard E Spiess, Daniel Bradbury, David S Kabakoff, Derek J Maetzold, Derek J Maetzold, Ellen Goldberg, Frank Stokes, Jeffrey E Eberwein, Kristen M Oelschlager, Tiffany Olson and Tobin W Juvenal.
View institutional ownership trends
.

How do I buy shares of Castle Biosciences?

Shares of CSTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CSTL) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners